Atibuclimab is a chimeric monoclonal antibody targeting CD14, consisting of a mouse variable region and a human IgG4 Fc region. Atibuclimab can be used to treat amyotrophic lateral sclerosis. Atibuclimab reduces LPS-induced disease and inhibits LPS-induced pro-inflammatory cytokine release, delaying the release of anti-inflammatory cytokine soluble TNF receptor type I.
Purity:
95.00%
CAS Number:
[2417175-94-9]
Target:
TLR|||TNF
* VAT and and shipping costs not included. Errors and price changes excepted